ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Brawn Biotech declared related party transaction filing under Regulation 23(9) non-applicable for FY 2025-26. Its paid-up capital and net worth are below the exemption thresholds.
Brawn Biotech Ltd reported revenue from operations of ₹5.6 Cr (+14.3% YoY) and net profit of ₹0 Cr for Q2 FY27.
Brawn Biotech intimated a board meeting on 05 Nov 2026 to consider un-audited Q2 FY27 results. The trading window stays closed till 16 Nov 2026.
Brawn Biotech Ltd has filed its quarterly shareholding pattern for the period ending September 30, 2026. The filing includes details on promoter and public shareholding.
Brawn Biotech Ltd members approved the appointment of M/s. GDSM and Co. as Statutory Auditors. Mr. Brij Raj Gupta was also re-appointed as Director at the Annual General Meeting.
Brawn Biotech Ltd held its 41st Annual General Meeting on September 29, 2026. All resolutions were passed by the shareholders with the requisite majority.
Brawn Biotech informed the exchange that it has issued letters to shareholders regarding the 41st AGM notice and annual report access.
Brawn Biotech Ltd has filed the notice for its 41st Annual General Meeting, scheduled to be held on September 29, 2026, via video conferencing.
Brawn Biotech Ltd reported revenue from operations of ₹6.1 Cr (+5.2% YoY) and net profit of ₹0.2 Cr (+0.0% YoY) for Q1 FY27.
Brawn Biotech Ltd has scheduled a Board Meeting for August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Brawn Biotech Ltd notified BSE regarding the non-applicability of Regulation 24A for Annual Secretarial Compliance Report. The company remains below the mandatory reporting thresholds for capital and networth.
Brawn Biotech Ltd reported revenue from operations of ₹2 Cr (-65.5% YoY) and net profit of ₹0.6 Cr (-53.8% YoY) for Q4 FY26.
Brawn Biotech Ltd reported standalone annual revenue of ₹17.43 Crore for FY26. The Board approved these audited financial results during its meeting on May 29, 2026.
Brawn Biotech scheduled a board meeting for May 29, 2026, to approve audited FY2026 financial results. The trading window remains closed until June 1, 2026.